DURECT Q3 revenues marginally fall
DURECT has posted a net loss of $4.65m for the third quarter 2010, or $0.05 loss per diluted share, compared to net loss of $5.54m, or $0.07 loss
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.